Suppr超能文献

[血管紧张素转换酶抑制剂治疗动脉高血压]

[Angiotensin-converting-enzyme inhibition in arterial hypertension].

作者信息

Waeber B, Nussberger J, Brunner H R

机构信息

Division Départment de médecine interterne, Centre Hospitalier Universitaire Vaudois, Lausanne, Schweiz.

出版信息

Wien Med Wochenschr. 1990 Jan 31;140(1-2):22-30.

PMID:2408247
Abstract

Angiotensin converting enzyme (ACE) inhibitors were developed to prevent the generation of angiotensin II and thereby to reduce peripheral vasoconstriction. These drugs have already proven their efficacy in the management of essential hypertension as well as of various forms of secondary hypertension. When given alone or in combination with other antihypertensive agents, they allow to normalize blood pressure of almost all patients. These compounds have favorable effects on hemodynamics and regional blood flow distribution. They do not affect lipid metabolism and have usually no deleterious influence on the quality of life. In view of their efficacy and tolerability profile, ACE inhibitors are likely to become widely used as first choice antihypertensive agents.

摘要

血管紧张素转换酶(ACE)抑制剂的研发目的是阻止血管紧张素II的生成,从而减轻外周血管收缩。这些药物已在原发性高血压以及各种继发性高血压的治疗中证明了其疗效。单独使用或与其他抗高血压药物联合使用时,它们能使几乎所有患者的血压恢复正常。这些化合物对血液动力学和局部血流分布有良好影响。它们不影响脂质代谢,通常对生活质量也没有有害影响。鉴于其疗效和耐受性,ACE抑制剂很可能会广泛用作首选抗高血压药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验